UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000038573
Receipt No. R000043959
Scientific Title A comprehensive research on identifying factors to predict transition to psychosis in participants at At-Risk Mental State by using Rorschach profiles and stress-related biomarkers in saliva.
Date of disclosure of the study information 2019/11/15
Last modified on 2019/11/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A comprehensive research on identifying factors to predict transition to psychosis in participants at At-Risk Mental State by using Rorschach profiles and stress-related biomarkers in saliva.
Acronym Predictive factors for transition to psychosis in ARMS subjects
Scientific Title A comprehensive research on identifying factors to predict transition to psychosis in participants at At-Risk Mental State by using Rorschach profiles and stress-related biomarkers in saliva.
Scientific Title:Acronym Predictive factors for transition to psychosis in ARMS subjects
Region
Japan

Condition
Condition schizophrenia, At-Risk Mental State
Classification by specialty
Psychiatry
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The objective is to explore predictive biomarkers in At Risk Mental State (ARMS) subjects during transition to psychosis, focusing on changes in psychological characteristics and changes in stress-related biomarkers in saliva.
Basic objectives2 Others
Basic objectives -Others Comparison of Rorschach profiles and biomarkers between ARMS subjects, schizophrenia subjects and healthy controls.
Trial characteristics_1 Exploratory
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes (a)Rorschach test
(b)Structured Interview for Prodromal Syndromes: SIPS
(c)The Scale of Prodromal Symptoms: SOPS
(d)Cortisol in saliva 2ml: alpha-Amylase, CRP (C-Reactive Protein), IL-6, IL-1-beta, in saliva.
Key secondary outcomes (a)the Scale to Assess Unawareness of Mental Disorder Japanese Version: SUMD-J
(b)Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version: SWNS-J
(c)Positive and Negative Syndrome Scale: PANSS
(d)The Brief Assessment of Cognition in Schizophrenia: BACS
(e)Beck Depression Inventory-2: BDI-2
(f)Height, weight, smoking status

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit
40 years-old >=
Gender Male and Female
Key inclusion criteria Basic standards
1)Provide consent to sample bioinformation, capable and willing to follow the research process.
2)Age between 15 to 40
3)Total IQ higher than or equal to 70

UHR group
1)Meet at least one out of the three types of symptomatology as below (You should be aware that the three types of prodromal symptoms are not mutually exclusive. A patient may fulfill more than one type of symptomatology).
The Criteria of Prodromal Syndromes: COPS
A)Brief Intermittent Psychotic Syndromes: BIPS
B)Attenuated Positive Symptom Syndrome: APSS
C)Genetic Risk and Deterioration Syndrome: GRDS

Health Controls
1)Healthy controls, who were age and sex matched with UHR group.
Key exclusion criteria 1)Those who have neurologic or medical neurologic or medical conditions as below: history of head trauma with loss of consciousness, chronic pulmonary disease, kidney disease, chronic liver disease, thyroid disease, active cancer, cerebrovascular disease, epilepsy, neurological disorder, substance related disorder, or mental retardation(IQ<70), obvious history of psychosis.
2)Those who are not seeking for help.
3)Those who suffer from autoimmune disease (SLE, hyperthyroidism: Graves' disease, ulcerative colitis, Crohn's disease).
4)Regular use of steroid or NSAID.
5)The attending physician decided that the patient was inappropriate to participate in the study.
Target sample size 168

Research contact person
Name of lead principal investigator
1st name Tsubasa
Middle name
Last name Morimoto
Organization Nara Medical University
Division name Department of Psychiatry Psychiatric Institute
Zip code 6348522
Address 840 Shijocho Kashihara Nara
TEL +81-744-22-3051
Email tsubasa@naramed-u.ac.jp

Public contact
Name of contact person
1st name Naoko
Middle name
Last name Kishimoto
Organization Nara Medical University
Division name Department of Psychiatry Psychiatric Institute
Zip code 6348522
Address 840 Shijocho Kashihara Nara
TEL +81-744-22-3051
Homepage URL
Email naoko@naramed-u.ac.jp

Sponsor
Institute Nara Medical University
Institute
Department

Funding Source
Organization Japan Science and Technology Agency
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Nara Medical University
Address 840 Shijocho Kashihara Nara
Tel +81-744-22-3051
Email naoko@naramed-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 11 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2019 Year 04 Month 24 Day
Date of IRB
2019 Year 08 Month 21 Day
Anticipated trial start date
2019 Year 08 Month 21 Day
Last follow-up date
2025 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information nothing special

Management information
Registered date
2019 Year 11 Month 13 Day
Last modified on
2019 Year 11 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043959

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.